Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio dosed the first patient in its global Phase 2b ASCENTRA-UC trial of once-daily oral PALI-2108 in roughly 204 patients with moderately to severely active ulcerative colitis. Site activation is ahead of schedule with 29 of 30 planned U.S. sites live; the company targets ~115 total sites globally, with Canada CTA clearance and European submissions under review. The primary endpoint is clinical remission at Week 12, with a 36-week maintenance phase through Week 48.
Key figures
- Drug Name
- PALI-2108
- Phase Of Trial
- Phase 2b
- Topline readout
- Q4 2027
- Planned enrollment
- 204
- Us sites activated
- 29 of 30
- Total planned sites
- ~115
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.